The sales of sepsis diagnostics are expected to grow at a CAGR of over 8% through 2032, according to Fact.MR revised MR’s estimate, which predicts a strong development trajectory for FY 2021–22 and beyond. The coronavirus pandemic, which was linked to the emergence of pneumonia-induced sepsis and subsequent mortality, significantly boosted growth prospects.
The estimate predicts that the market would bring in approximately US$ 1,630 Million in revenue by 2032, providing significant short-term benefits. These are largely connected to ongoing R&D initiatives, as well as a rise in patient sepsis brought on by ICU and hospital admission. Modern automated technology is being adopted by manufacturers to deliver a precise and quick diagnosis.
Important conclusions from the market study
• By 2032, the market for sepsis diagnostics will have more than doubled in size.
• Demand for tests and reagents will reach US$ 300 million in value by 2032, broken down by product.
• The U.S. market is anticipated to grow at a 7.8% value CAGR and be opportunistic.
• The CAGRs for Germany and India will be 7% and 6.6%, respectively.
• By the conclusion of the projection period, China will produce a market worth $750 million.
• The demand for sepsis diagnostics will reach US$ 755 million by 2022.
Key Sepsis Diagnostics Service Providers
- BioMerieux SA
- Becton Dickinson and Company (BD)
- Thermo Fisher Scientific Inc.
- Abbott Laboratories Inc.
- Roche Holdings AG
